Dupont Jakob 4

What Happened
Dupont Jakob, a director of Pyxis Oncology (PYXS), exercised 35,000 stock options and sold 35,000 common shares on June 30, 2026. The exercise cost reported was $1.60 per share (total $56,000). The shares were sold in multiple trades at a weighted average price of $3.06 per share, yielding proceeds of $107,100. The filing also reports a separate derivative disposition of 35,000 shares at $0.00 (no further detail provided in the filing).

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely).
• Exercise: 35,000 options exercised at $1.60/share — total exercise cost $56,000. (Code M)
• Sale: 35,000 shares sold at weighted avg $3.06/share — total proceeds $107,100. (Code S)
• Report notes: sales executed under a Rule 10b5-1 trading plan adopted Sept 24, 2025 (F1). Sales executed in multiple trades with prices ranging $3.00–$3.36 (F2, F3).
• Option award details: Award vests in three equal annual tranches from Aug 23, 2023 (vesting commencement Aug 23, 2024) per filing (F4).
• Shares owned after the transactions: not disclosed in the information provided.

Context
This filing shows an option exercise followed by immediate sale of the resulting shares, commonly a cashless exercise/sell pattern and here executed under a pre-established 10b5-1 plan (which typically schedules trades to avoid timing questions). The zero-price derivative disposition is listed in the filing but not explained further in the report. This is a routine director transaction; the filing does not state any change in board status or other corporate developments.